← Eichor
Condition: Primary Myelofibrosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Primary Myelofibrosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Phase 1 · 4 location(s) · Cellenkos, Inc. · NCT05423691AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positiv
Phase 3 · 42 location(s) · University Hospital, Brest · NCT05198960Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye
Phase 1 · 29 location(s) · Incyte Corporation · NCT05936359A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination Wi
Phase 1 · 8 location(s) · Geron Corporation · NCT05371964A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Phase 1/Phase 2 · 28 location(s) · Disc Medicine, Inc · NCT05320198Myeloproliferative Neoplastic Diseases Observatory From Brest
Phase N/A · 1 location(s) · University Hospital, Brest · NCT02897297A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK I
Phase 1/Phase 2 · 12 location(s) · iOnctura · NCT06887803RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Phase 2 · 18 location(s) · Ryvu Therapeutics SA · NCT06397313Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age
Phase N/A · 1 location(s) · University Hospital, Bordeaux · NCT06022328Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk M
Phase 2 · 2 location(s) · University of Southern California · NCT06063486Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 · 9 location(s) · Icahn School of Medicine at Mount Sinai · NCT05835466A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Phase 1 · 30 location(s) · Incyte Corporation · NCT06313593Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 · 1 location(s) · University of Chicago · NCT03326310Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Phase 1 · 1 location(s) · Eilean Therapeutics AU Pty Ltd · NCT07527221Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Phase N/A · 26 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06516406Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CA
NA · 10 location(s) · University Hospital, Angers · NCT04942080An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/Phase 2 · 2 location(s) · University of California, Irvine · NCT05123365Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Asian Myeloproliferative Neoplasm (MPN) Registry
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05882773Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Phase 1 · 54 location(s) · Incyte Corporation · NCT0744169468Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
Phase N/A · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151119Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.